Ocugen Founder-CEO Musunuri on mutation-agnostic gene therapy and COVID-19 vaccine plans

Ocugen’s founder and CEO Shankar Musunuri speaks to Scrip about his company’s mutation-agnostic gene therapy candidate OCU-400, a commercial agreement with CanSino Biologics and plans for a bridging study of partner Bharat Biotech’s COVID-19 vaccine Covaxin post a US FDA clinical hold.